

# Comparative Effectiveness – A Key to Health Care Reform

---

**Gail R. Wilensky**

Project HOPE

September 22, 2008



# We All Agree on the Problems

---

- ◆ Unsustainable spending growth
- ◆ Lots of problems with patient safety
- ◆ Lots of problems with quality/clinical appropriateness



And, of course—the uninsured

# Slowing Spending/Improving Value is Critical

---



- ◆ ↑ in spending is biggest driver of uninsured
- ◆ Improved value/slower growth will facilitate coverage expansions
- ◆ Rising health care costs putting huge pressures on:  
Employers, Employees, Federal Budget

# What We Know


---



- ◆ Huge variations in care exist
- ◆ Spending *more* not the same as *more quality*
- ◆ Spending growth partly relates to technology growth, need to learn how to “*spend smarter*”
- ◆ Spending growth largely related to growth in chronic disease, need to learn how to “*treat smarter*”

# To Change Where We Are...

---



- ◆ We need to *measure better*
  - need a “score-card”
  - quality, efficiency, “patient-centeredness”
- ◆ We need *better information*
- ◆ We need to *change the incentives*
  - *Medicare* – 25 years getting it exactly *wrong!*
  - *Private Sector* – not much better

# Better Data is Starting to be Available

---



- ◆ “Hospital Compare” - public data
- ◆ New P4P measures being collected for docs  
Really P4R, started July 1, 2007
- ◆ JCAHO “Quality Check” – Public reporting

# *Need More Data; Better Data*

---



Means a major investment in

*Comparative Effectiveness information*

That is ... Information on...

“What works when, for whom, provided by...”

*also...*

Recognition that “technology” is rarely  
*always* effective or *never* effective

# CCE Needs the Right Focus

---



Elemental building blocks to “spending smarter”

- ◆ Focus on *conditions* rather than *interventions/therapeutics*; *procedures*, not just Rx and devices
- ◆ Invest in what is not yet known; use what is known more effectively

*Dynamic Process...*



# Comparative Effectiveness Should Include Data from Many Sources

---



- ◆ “Gold Standard” - - double-blinded RCT
- ◆ “Real World” RCT (Sean Tunis)
- ◆ Epidemiological studies; medical record analyses
- ◆ Administrative data

Need to understand: All data have limitations

# How to Bring in Cost-Effectiveness

---



- ◆ Fund cost-effectiveness studies with same funding stream as CCE
- ◆ Strong preference to keeping activities separate
  - at AHRQ or CMS or wherever
- ◆ CMS needs new authority to use C/E
  - reimbursement vs. coverage
- ◆ Private payers can fund additional C/E studies
  - universities; free standing centers

# “Spending Smarter” Also Means Better Incentives

---



- ◆ Need to realign financial incentives
- ◆ Reward institutions/clinicians who provide high quality/efficiently produced care
- ◆ Use “Value-based” insurance in private sector
- ◆ Reward healthy lifestyles by consumers

# Will Better Information, Better Information Systems and Better Incentives --

---


- ◆ Improve Values?

Yes, should improve values

- ◆ Moderate spending growth rates?

Should – but don't know for sure

Better than the Alternatives!



# Lots of Interest

---



- ◆ Some interest across the political parties
- ◆ Industry support is mixed –
  - Big pharma ok as long as transparent process, minimal extra delay
  - Small pharma/biotech worried about delays;
  - Device companies nervous about small incremental improvements
- ◆ Physician groups beginning to “declare themselves

# What Next?

---



- ◆ Congressional interest continues...
  - Part of CHAMP bill passed in August; superseded by Senate
  - Baucus/Conrad Bill introduced August 2008
- ◆ Presidential candidate's recognize imp. of CCE  
2009 should be the year!